Celtaxsys, Inc. Information
Contact top employees from
Celtaxsys, Inc.
Summary
Celtaxsys, Inc. is a private company that has been in the industry for 20 years. The company currently specializes in the Pharmaceuticals, Pharmaceuticals, Biotechnology areas. The position of the President & CEO is occupied by Greg Duncan. Its headquarters is located at Atlanta, Georgia, USA. The number of employees ranges from 1 to 25. The annual revenue of Celtaxsys, Inc. varies between 5.0M and 25M. Total funding of the company - $32.9M. To connect with Celtaxsys, Inc. employee register on SignalHire.
Industries
Pharmaceuticals
Headquarters Location
Employees Size
10-50 employees
Specialties
Inflammation, Cystic Fibrosis
SIC Code
2834, 2836
DMA Code
Atlanta Metropolitan Area
Founded
2005
Estimated Annual Revenue
$5.0M - 25M
Operating Status
Independent Company
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2014 | Public Company | 25 - 100 | 2.7M | $93.9M | |
| 2015 | Privately Held | 100 - 250 | 16.7M | $251M | |
| 2016 | - | 250 - 500 | 2.5M | $20.7M | |
| 1981 | Privately Held | 250 - 500 | 50M | $0 | |
| 2008 | - | 100-200 | - | $- | |
| 2014 | - | 200-500 | - | $- |
Employees Turnover 3 quarter 2025
Length of Employment
Employee tenure at Celtaxsys, Inc. shows a diverse range of experience levels:
13% for 5–7 years19% for 8–10 years69% have over 11 years of service at Celtaxsys, Inc.Contact top employees from
Celtaxsys, Inc.
Gary Flynn
Consultant
Gerry Brunk
Board of Directors Member
Ralph Grosswald
Vice President of Operations
Similar Companies
FAQ
Celtaxsys, Inc. operates in the Pharmaceuticals industries. More details can be found on the official website: celtaxsys.com.
The headquarters of Celtaxsys, Inc. are located in Atlanta, United States.
The current CEO of Celtaxsys, Inc. is Greg Duncan
You can contact Celtaxsys, Inc. by phone at 1-470-206-0153.
Celtaxsys, Inc. currently employs 10-50 people.
Celtaxsys, Inc.'s revenue is approximately 11.4M.
Well-known competitors of Celtaxsys, Inc. include Corbus Pharmaceuticals, Codiak BioSciences, Artizan Biosciences, Inc. and BioGenex.
